Mirum Pharmaceuticals charts a distinct course in the rare disease biotech landscape, leveraging strategic acquisitions to build a broad, sustainable pipeline while navigating a complex regulatory environment.
Barclays initiates coverage of 4D Molecular Therapeutics with an Overweight rating and a $33 price target, citing a favorable industry backdrop with potential M&A tailwinds and shifting focus away from drug pricing pressures. The gene therapy developer also outlined key clinical milestones expected through 2026.
Bank of America has raised its price target for clinical-stage biopharma firm Xencor (XNCR), highlighting a cautiously improving landscape for the sector driven by data catalysts, M&A, and capital access.
Biogen (BIIB) is set to report fourth-quarter earnings before the bell Friday, with Wall Street anticipating a year-over-year revenue decline. The results come amid a mixed landscape for biotechnology peers and broader economic uncertainties.
Eikon Therapeutics, a biotech firm founded by Nobel laureate Eric Betzig, raised $381.2 million in its Nasdaq debut, pricing shares at $18. The offering signals renewed investor confidence in the biotech IPO market after a prolonged slowdown.
Veradermics Inc., a clinical-stage biopharmaceutical company developing a novel treatment for pattern hair loss, priced its IPO above expectations, raising $256.3 million and achieving a market valuation of nearly $600 million. The offering signals renewed investor appetite for biotech listings.
Goldman Sachs, Clear Street, and Bank of America have all significantly raised their price targets for Krystal Biotech (KRYS), citing strong growth from its gene therapy Vyjuvek and a promising pipeline targeting ophthalmic and respiratory diseases.
Legend Biotech shares have plummeted nearly 50% in three months, erasing billions in market value and forcing investors to question whether the selloff is an overreaction or a prudent reassessment of the CAR-T leader's long-term prospects.
Recent volatility in Genscript Biotech's (SEHK:1548) share price has investors questioning its true worth. While short-term gains offer a glimmer, a deeper look reveals a stark three-year decline, setting the stage for a critical valuation debate.
Arcellx (ACLX) shares are caught in a tug-of-war between conflicting valuation signals. While a sky-high price-to-book ratio suggests the stock is richly valued, a discounted cash flow model implies massive upside potential. We examine the data behind the biotech's recent price swings and what investors are really betting on.
Amid forecasts of rising economic stress and market volatility in 2026, investment bank Houlihan Lokey (NYSE: HLI) is attracting bullish attention for its dual strength in M&A advisory and corporate restructuring. Analysts point to its defensive positioning and potential to capture outsized gains in a shifting financial landscape.
Amid a challenging market for biotech, C4 Therapeutics (NASDAQ: CCCC) is drawing investor attention with its targeted protein degradation platform. Backed by industry giants and focused on niche cancers, the clinical-stage company presents a high-risk, high-reward proposition. We examine the bull case and the road ahead.
Investment firm Hussman Strategic Advisors has liquidated its entire stake in TG Therapeutics, a move that comes as the biotech's stock lags behind broader market gains despite reporting strong revenue growth for its flagship product.
Clinical-stage biotech Erasca (ERAS) has seen its stock skyrocket over the past 12 months, hitting a multi-year high. While technical momentum is strong, the company remains pre-revenue, with its fate tied to future drug approvals, presenting a classic high-risk, high-reward scenario for investors.
German biotech firm AMSilk partners with Italian mill Pure Denim to launch a new category of high-performance, sustainable denim infused with lab-grown spider silk proteins, targeting the luxury market with enhanced comfort and eco-credentials.
Shares of clinical-stage biotech Scholar Rock (NASDAQ: SRRK) have surged nearly 60% in three months, closing at $44.34. This rally, backed by promising clinical progress, has investors weighing its premium valuation against its long-term potential in treating serious diseases.
While Legend Biotech's CAR-T therapy Carvykti missed Q4 sales estimates, prompting mixed analyst reactions, some firms emphasize its curative potential and view the stock's recent decline as a strategic entry point for investors.
While investors chase AI and big tech, a niche biotech firm focused on rare genetic obesity disorders has quietly delivered staggering returns, with Wall Street seeing further 40% upside. Rhythm Pharmaceuticals' targeted approach and upcoming catalysts have analysts bullish, despite its relative anonymity.
Investment firm Tanager Wealth Management has fully divested its position in Centessa Pharmaceuticals, capitalizing on the biotech's near-60% annual surge. The move highlights strategic portfolio rebalancing as the stock's rally potentially amplified its risk profile within a diversified fund.
UBS has launched coverage of Arcellx with a Buy rating and a $100 price target, signaling growing Wall Street confidence in a biotech sector recovery and spotlighting the company's promising CAR-T therapy for multiple myeloma.
